Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 microg/ml. Ninety percent of the strains tested were inhibited by 256 microg/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.
Finegold
S M
SM
Department of Medicine, Medical and Research Services, VA Greater Los Angeles Healthcare System, UCLA School of Medicine, Los Angeles, California 90073, USA. sidfinegol@aol.com
Molitoris
D
D
Väisänen
M-L
ML
D000667:Ampicillin / Q000494:pharmacology; D001421:Bacteria, Anaerobic / Q000187:drug effects*; D005243:Feces / Q000382:microbiology*; D008826:Microbial Sensitivity Tests; D009355:Neomycin / Q000494:pharmacology; D009574:Nitro Compounds; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin; D013407:Sulbactam / Q000494:pharmacology; D017334:Teicoplanin / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D009574:Nitro Compounds; D012294:Rifamycins; D013844:Thiazoles; D017334:Teicoplanin; D014640:Vancomycin; D000667:Ampicillin; D009355:Neomycin; D000078262:Rifaximin; D013407:Sulbactam; C041747:nitazoxanide